Advanced Search Results For "schizophrenia"
Your filters
Is ECT better than clozapine for treatment-resistant schizophrenia?
Publication Type: Editorial & Opinion
Source(s): Asian journal of psychiatry [Asian J Psychiatr] 2023 Dec; Vol. 90, pp. 103798. Date of Electronic Publication: 2023 Oct 11.
Abstract: Competing Interests: Declaration of Competing Interest NIL.
Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: A 1-year retrospective cohort study.
Publication Type: Academic Journal
Source(s): Acta psychiatrica Scandinavica [Acta Psychiatr Scand] 2023 Nov; Vol. 148 (5), pp. 437-446. Date of Electronic Publication: 2023 Sep 08.
Abstract: Introduction: No study has investigated the impact of smoking habits and concomitant valproic acid (VPA) use on clinical outcomes in maintenance treatment with clozapine. Thus, we aimed to examine the effect of smoking habits and concomitant VPA use on...
Reply to Dr Yucel's Comments on the Article "Long-term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
Publication Type: Editorial & Opinion
Source(s): Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2023 Nov-Dec 01; Vol. 43 (6), pp. 555-556.
Critical Feedback on Article by Lee and Colleagues: "Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
Publication Type: Editorial & Opinion
Source(s): Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2023 Nov-Dec 01; Vol. 43 (6), pp. 555.
Electroconvulsive therapy or clozapine for adolescents with treatment-resistant schizophrenia: an explorative analysis on symptom dimensions.
Publication Type: Academic Journal
Source(s): International journal of psychiatry in clinical practice [Int J Psychiatry Clin Pract] 2023 Sep; Vol. 27 (3), pp. 257-263. Date of Electronic Publication: 2022 Dec 28.
Abstract: Objective: This study sought to compare pre-intervention patient characteristics and post-intervention outcomes in a naturalistic sample of adolescent inpatients with treatment-resistant psychotic symptoms who received either electroconvulsive therapy ...
Long-term outcomes of deep brain stimulation for treatment-resistant schizophrenia: Exploring potential targets.
Publication Type: Academic Journal
Source(s): Journal of psychiatric research [J Psychiatr Res] 2023 Jul; Vol. 163, pp. 296-304. Date of Electronic Publication: 2023 May 18.
Abstract: Background: Schizophrenia is a complex and disabling disorder. Around 30% of patients have treatment-resistant schizophrenia (TRS).Objective: This study summarizes the outcomes after three years follow-up of the first series of patients with TRS treate...
Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia.
Publication Type: Academic Journal
Source(s): European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2023 Jul; Vol. 72, pp. 18-29. Date of Electronic Publication: 2023 Apr 13.
Abstract: Treatment-resistant schizophrenia (TRS) patient respond poorly to antipsychotics. Inflammatory imbalance involving pro- and anti-inflammatory cytokines may play an important role in the mechanism of antipsychotic-medication response. This study aimed t...
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.
Publication Type: Academic Journal
Source(s): The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2023 Aug 29; Vol. 26 (8), pp. 523-528.
Abstract: Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with 46-week extension, indicate very good tolerability with exceptional, clinically important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate modulator,...
The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.
Publication Type: Academic Journal
Source(s): Biomolecules [Biomolecules] 2023 Aug 05; Vol. 13 (8). Date of Electronic Publication: 2023 Aug 05.
Abstract: Almost 25% of schizophrenia patients suffer from obsessive-compulsive symptoms (OCS) considered a transdiagnostic clinical continuum. The presence of symptoms pertaining to both schizophrenia and obsessive-compulsive disorder (OCD) may complicate pharm...
Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
Publication Type: Academic Journal
Source(s): Psychiatry research [Psychiatry Res] 2023 Jul; Vol. 325, pp. 115217. Date of Electronic Publication: 2023 Apr 23.
Abstract: Treatment resistant schizophrenia (TRS) is characterized by repeated treatment failure with antipsychotics. A recent genome-wide association study (GWAS) of TRS showed a polygenic architecture, but no significant loci were identified. Clozapine is show...